摘要
探讨苯磺酸左旋氨氯地平联合厄贝沙坦治疗老年高血压临床疗效。选取在2023年1月—2024年6月大理市第一人民医院收治的82例老年高血压患者,随机分为对照组(41例,厄贝沙坦治疗)和观察组(41例,苯磺酸左旋氨氯地平联合厄贝沙坦治疗)。比较两组临床疗效、血液流变学指标(血浆黏度、全血低切黏度、全血高切黏度)、Apelin-12水平及不良反应发生率。结果显示,观察组总有效率高于对照组(P<0.05);治疗后,观察组血浆黏度、全血低切黏度和全血高切黏度显著均显著低于对照组,Apelin-12水平显著高于对照组(均P<0.05);两组不良反应发生率差异无统计学意义(P<0.05)。研究发现,苯磺酸左旋氨氯地平联合厄贝沙坦治疗老年高血压临床疗效显著,可有效改善患者血液流变学指标及Apelin-12水平,且安全性良好。
To explore the clinical efficacy of levamlodipine besylate combined with irbesartan in the treatment of elderly patients with hypertension.A total of 82 elderly patients with hypertension admitted to No.1 People's Hospital of Dali City from January 2023 to June 2024 were selected and randomly divided into a control group and an observation group,with 41 cases in each group.The control group was treated with irbesartan,while the observation group was treated with levamlodipine besylate combined with irbesartan.The clinical efficacy,hemorheological indicators(plasma viscosity,whole blood low-shear viscosity,whole blood high-shear viscosity),Apelin-12 level,and incidence of adverse reactions were compared between the two groups.The results showed that the total effective rate of the observation group was higher than that of the control group(P<0.05);after treatment,the plasma viscosity,whole blood low-shear viscosity,and whole blood high-shear viscosity in the observation group were significantly lower than those in the control group,and the Apelin-12 level was significantly higher than that in the control group(all P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).The study concluded that levamlodipine besylate combined with irbesartan has a significant clinical efficacy in the treatment of elderly patients with hypertension,which can effectively improve the patients’hemorheological indicators and Apelin-12 level,with good safety.
作者
赵丽华
Zhao Lihua(No.1 People's Hospital of Dali City,Dali,Yunnan 671000)
出处
《中外健康》
2025年第7期133-136,共4页
World Health
